Bio Pharma Dive

OCTOBER 26, 2022

The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.

Protein 294

Protein Antibody Medicine Drugs 294

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody 147

Antibody Development Protein 147

Bio Pharma Dive

AUGUST 14, 2023

Elrexfio is the third bispecific antibody cleared to treat the blood cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.

FDA Approval 246

FDA Approval Protein Antibody Drugs 246

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Pharmaceutical Technology

JUNE 10, 2024

Discover Vir Biotechnology's groundbreaking patent for a monoclonal antibody targeting Staphylococcus aureus infections. Learn how this innovative composition binds to key proteins for potential treatment.

Antibody 130

Antibody Protein 130

Pharmaceutical Technology

JULY 1, 2022

Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. .

Antibody 147

Antibody Development Licensing Licensing 147

Scienmag

DECEMBER 16, 2021

MADISON — Small, unique antibody-like proteins known as VNARs — derived from the immune systems of sharks — can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec.

Protein 87

Protein Antibody Medicine 87

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Development 147

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.

Antibody 105

Antibody FDA Approval HR Trials 105

Bio Pharma Dive

MAY 17, 2024

Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.

FDA Approval 187

FDA Approval Protein Antibody Drugs 187

Bio Pharma Dive

OCTOBER 28, 2020

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.

Development 206

Development Drugs Protein Antibody 206

Bio Pharma Dive

JANUARY 17, 2023

The deal gives Leap several early-stage drug candidates, including an antibody targeting the protein Claudin 18.2, which has lately drawn several other biotech companies’ interest.

Protein 202

Protein Antibody Drugs 202

Bio Pharma Dive

MAY 15, 2024

Uniquity Bio emerged from stealth mode ready to begin Phase 2 trials of an antibody targeting the protein TSLP in asthma and COPD.

Protein 180

Protein Antibody Drugs Trials 180

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 It is self-assembled into stable trimeric protein particles with the addition of squalene-based oil-in-water emulsion adjuvant following purification and mixing.

Vaccine 269

Vaccine Vaccination Protein HR 269

STAT News

DECEMBER 10, 2022

NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might offer a new way to get the immune system to hunt down and destroy multiple myeloma cells. Now, the results of a Phase 2 study on a bispecific antibody targeting this protein offers confirmation.

Antibody 132

Antibody Protein Trials Research 132

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 193

Protein Antibody Medicine Drugs 193

XTalks

FEBRUARY 5, 2025

That was followed by a full approval for the same patient subset in December 2022, making it the first FDA-approved monoclonal antibody to treat COVID-19. In June 2021, the FDA granted emergency use authorization (EUA) for Actemra to treat hospitalized COVID-19 patients. It also has EUA for children aged between two and 18.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

Pharmaceutical Technology

MAY 30, 2023

It was granted based on data from the Phase III study, which demonstrated that the vaccine induced neutralising antibodies against the SARS-CoV-2 original strain. SKYCovion, a protein-based vaccine created in collaboration with GSK’s pandemic adjuvant, is suitable for storage between 2° and 8° Celsius.

Vaccine 298

Vaccine Vaccination Protein Medicine 298

pharmaphorum

NOVEMBER 6, 2022

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. AI for accelerated antibody discovery.

Antibody 123

Antibody Drugs Protein Life Science 123

Bio Pharma Dive

JUNE 5, 2023

Results from a “basket” trial of the antibody-drug conjugate show it shrank tumors across a half dozen cancers, suggesting a broader role to targeting the protein HER2.

Drugs 187

Drugs Protein Antibody Trials 187

Bio Pharma Dive

JULY 9, 2024

The Series A round will help the startup bring its lead candidate, an antibody aimed at the protein iRhom2, into human testing by the end of 2024.

Protein 164

Protein Antibody Drugs 164

Bio Pharma Dive

JUNE 16, 2023

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.

FDA Approval 180

FDA Approval Drugs Protein Antibody 180

Pharmaceutical Technology

JANUARY 4, 2023

TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity. The Gremlin1 protein was found to promote lineage plasticity while driving castration resistance in prostate cancer.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Bio Pharma Dive

SEPTEMBER 7, 2023

The alliance, which aims to combine Seagen’s antibody expertise with Nurix’s targeted protein degradation research, comes as the larger biotech awaits its acquisition by Pfizer to close.

Protein 180

Protein Antibody Drugs Research 180

Scienmag

NOVEMBER 17, 2021

Chemical topology is a unique dimension for protein engineering. Over the past few years, the discovery of topological nontrivial proteins in nature has already revealed their many potential functional benefits, such as enhanced thermal/mechanical/chemical stability.

Protein 80

Protein Antibody Engineer Development 80

BioPharma Reporter

NOVEMBER 9, 2023

The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).

Antibody 105

Antibody Drugs Protein Trials 105

Medical Xpress

MAY 16, 2023

Antibodies are proteins produced by our immune system, that protect us from foreign antigens that enter our body. Generally, an antibody only binds to one antigen via an epitope. These bind to antigens through epitopes, i.e., binding sites on antigens, to subsequently eliminate them.

Antibody 98

Antibody Protein 98

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Protein 124

Scienmag

MAY 23, 2021

Credit: Correspondence to – Chandra Mohan – cmohan@central.uh.edu Oncotarget published “Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens” which reported that the current study examines urine samples from 66 subjects, comprising of 31 Urology clinic controls […].

Protein 89

Protein Antibody Medicine 89

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccine 264

Vaccine Vaccination Protein Clinical Trials 264

Medical Xpress

APRIL 25, 2023

In a new investigation, scientists from La Jolla Institute for Immunology (LJI) have shown how antibodies, collected from this clinical study volunteer, bind to the SARS-CoV-2 "Spike" protein to neutralize the virus. An anonymous San Diego resident has become a fascinating example of how the human immune system fights SARS-CoV-2.

Antibody 98

Antibody Protein Scientist 98

BioSpace

JUNE 19, 2024

Vaxxinity published data from an early-stage clinical trial showing that its investigative immunotherapy, UB-312, could improve movement in Parkinson’s disease and protect against pathological alpha-synuclein.

Protein 97

Protein Antibody Clinical Trials Clinical Trials 97

Pharmaceutical Technology

JANUARY 19, 2023

This DUX4 protein abnormal expression leads to modifications in gene expression in muscle cells which are associated with progressive muscle function loss in FSHD patients. Avidity Biosciences’ AOC 1020 is intended to reduce the DUX4 mRNA and DUX4 protein expression in muscles in these patients.

Gene Expression 246

Gene Expression Gene Protein RNA 246

Pharmaceutical Technology

NOVEMBER 14, 2022

The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly. binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4.

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

MARCH 17, 2023

This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients. An ADC includes a monoclonal antibody, which helps recognise a protein that is present in the cancer cells and is bound to the payload, a cytotoxic agent.

Research 246

Research Antibody Protein Trials 246

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Scienmag

JANUARY 25, 2022

An international team of scientists has determined the precise structural changes in the spike protein of the omicron variant. Their observations explain how the virus is able to evade antibodies against previous variants and still remain highly infectious.

Protein 79

Protein Scientist Antibody 79